HLA class I immune editing in JAK2 V617F and CALR exon 9 mutation driven myeloproliferative malignancies

被引：0
|
作者：
Ivanova, Milena [1 ]
Tsvetkova, Gergana [2 ]
Micheva, Iliana [3 ]
Lessichkova, Spaska [1 ]
Petrova, Zasmina [4 ]
Ivanova, Anela [4 ]
Madjarova, Galja [4 ]
Hadjiev, Evgueniy [2 ]
Shivarov, Velizar [5 ]
机构：
[1] Med Univ, Univ Hosp Alexandrovska, Dept Clin Immunol, Sofia, Bulgaria
[2] Med Univ, Univ Hosp Alexandrovska, Dept Clin Hematol, Sofia, Bulgaria
[3] Med Univ, Univ Hosp Sveta Marina, Clin Hematol, Varna, Bulgaria
[4] Sofia Univ St Kl Ohridski, Fac Chem & Pharm, Dept Phys Chem, Sofia, Bulgaria
[5] Med Univ Pleven, Dept Expt Res, Pleven, Bulgaria
来源：
HLA | 2023年 / 101卷 / 04期
关键词：
D O I：
暂无
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
P2
引用
收藏
页码：366 / 367
页数：2
相关论文
共 50 条
  • [31] MHC CLASS I GENOTYPE SHAPES JAK2 V617F DRIVEN LEUKEMOGENESIS
    Ivanova, Milena
    Tzvetkova, Gergana
    Lukanov, Tzvetelin
    Nedyalkova, Antoaneta
    Stoimenov, Angel
    Naumova, Elissaveta
    Hadjiev, Evgueniy
    Shivarov, Velizar
    HLA, 2020, 95 (04) : 280 - 281
  • [32] The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders
    Scott, LM
    Campbell, PJ
    Baxter, EJ
    Todd, T
    Stephens, P
    Edkins, S
    Wooster, R
    Stratton, MR
    Futreal, PA
    Green, AR
    BLOOD, 2005, 106 (08) : 2920 - 2921
  • [33] No evidence for amplification of V617F JAK2 in myeloproliferative disorders
    Jones, A. V.
    Bunyan, D. J.
    LEUKEMIA, 2007, 21 (12) : 2561 - 2563
  • [34] MOLECULAR STUDY OF CALR GENE: MYELOPROLIFERATIVE NEOPLASMS (MPN) WITH NEGATIVE PHILADELPHIA AND JAK2/V617F
    Culurgioni, F.
    Musiu, C.
    Uda, S.
    Benziane, A.
    Pettinau, M.
    Usala, E.
    Cabras, M. G.
    HAEMATOLOGICA, 2017, 102 : 167 - 168
  • [35] No evidence for amplification of V617F JAK2 in myeloproliferative disorders
    A V Jones
    D J Bunyan
    N C P Cross
    Leukemia, 2007, 21 : 2561 - 2563
  • [36] Differential modulation of mutant CALR and JAK2 V617F-driven oncogenesis by HLA genotype in myeloproliferative neoplasms
    Shivarov, Velizar
    Tsvetkova, Gergana
    Micheva, Ilina
    Hadjiev, Evgueniy
    Petrova, Jasmina
    Ivanova, Anela
    Madjarova, Galia
    Ivanova, Milena
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [37] JAK2 V617F: implications for thrombosis in myeloproliferative diseases
    Hexner, Elizabeth O.
    CURRENT OPINION IN HEMATOLOGY, 2007, 14 (05) : 450 - 454
  • [38] Aquagenic pruritus and the JAK2 V617F mutation
    Langabeer, S. E.
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2019, 44 (03) : E33 - E33
  • [39] JAK2 (V617F) mutation in healthy individuals
    Passamonti, Francesco
    Rumi, Elisa
    Pietra, Daniela
    Lazzarino, Mario
    Cazzola, Mario
    BRITISH JOURNAL OF HAEMATOLOGY, 2007, 136 (04) : 678 - 679
  • [40] The JAK2 V617F mutation in Philadelphia-negative chronic myeloproliferative disorders
    Stoj, Anastazja
    Rudzki, Zbigniew
    Stachura, Jerzy
    Sacha, Tomasz
    Czekalska, Sylwia
    JOURNAL OF CLINICAL PATHOLOGY, 2007, 60 (09) : 1070 - 1071
12345